SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on January 9, 2018. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed in the text of this filing. The document solely references the attachment of a corporate presentation used by management at investor conferences.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The filing includes Item 7.01, disclosing a corporate presentation (Exhibit 99.1) dated January 2018.
Legal Status of Information: The information contained in the attached presentation is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Corporate Presentation dated January 2018) for any forward-looking statements or strategic updates, as the 8-K text itself contains no operational data.
- Confirm that the presentation materials are not legally binding or incorporated by reference into the company's official SEC filings.
- Note the discrepancy in the request metadata: The filing is for Imprimis Pharmaceuticals, Inc., not "Harrow, Inc."